DBV Technologies (NASDAQ:DBVT) Coverage Initiated at StockNews.com

Stock analysts at StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a note issued to investors on Saturday. The brokerage set a “hold” rating on the stock.

Separately, JMP Securities reiterated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a research report on Friday, January 10th.

DBV Technologies Stock Performance

Shares of DBVT stock opened at $4.99 on Friday. The firm has a market cap of $102.64 million, a P/E ratio of -1.11 and a beta of 0.71. DBV Technologies has a fifty-two week low of $2.20 and a fifty-two week high of $8.32. The business’s 50 day moving average price is $4.48 and its 200-day moving average price is $3.84.

Institutional Investors Weigh In On DBV Technologies

An institutional investor recently bought a new position in DBV Technologies stock. Boxer Capital Management LLC purchased a new stake in shares of DBV Technologies S.A. (NASDAQ:DBVT) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 50,000 shares of the company’s stock, valued at approximately $154,000. Boxer Capital Management LLC owned approximately 0.24% of DBV Technologies as of its most recent SEC filing. Hedge funds and other institutional investors own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.